You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 40 No. 7, July 1983 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Anterior Pituitary Hormone Secretion in Chronic Schizophrenics

Responses to Administration of Hypothalamic Releasing Hormones

I. Nicol Ferrier, MRCPsych; Eve C. Johnstone, MD; Timothy J. Crow, FRCP; Isobel Rincon-Rodriguez, PhD

Arch Gen Psychiatry. 1983;40(7):755-761.


Abstract

• Venous samples were obtained serially from 18 chronic schizophrenics and nine controls before and after the intravenous administration of protirelin and gonadorelin (gonadotropin releasing hormone [GnRH]) and by venipuncture from 38 controls. Significant reductions in basal luteinizing hormone (LH) and follicle-stimulating hormone (FSH) were found in the schizophrenic group associated with a reduction in the fluctuation of LH in serial samples. The FSH and prolactin responses to the administration of protirelin and gonadorelin were reduced in the schizophrenic group and abnormal increments of growth hormone secretion were noted in a number of patients, particularly those with reduced basal and stimulated hormone secretion. This pattern of hypothalamic-pituitary dysfunction, which is distinct from that seen in other psychiatric and endocrinological conditions, suggests a reduction in spontaneous GnRH release from the hypothalamus in schizophrenia and may be of potential pathophysiological significance.



Author Affiliations

From the Division of Psychiatry, Clinical Research Centre, Harrow, Middlesex, England (Drs Ferrier, Johnstone, and Crow); and the World Health Organization Collaborating Centre, Chelsea Hospital for Women, London (Dr Rincon-Rodriguez).


Footnotes

Accepted for publication Aug 19, 1982.

Reprint requests to Division of Psychiatry, Clinical Research Centre, Harrow, Middlesex, England HA1 3UJ (Dr Ferrier).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effects of Bisphenol-A and Other Endocrine Disruptors Compared With Abnormalities of Schizophrenia: An Endocrine-Disruption Theory of Schizophrenia
Brown
Schizophr Bull 2009;35:256-278.
ABSTRACT | FULL TEXT  

Evaluating Prolactin Response to Dopamine Agonists in Schizophrenia: Methodological Problems
Davis et al.
Arch Gen Psychiatry 1985;42:259-264.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1983 American Medical Association. All Rights Reserved.